An official journal of the Infectious Diseases Society of America. Publishes clinical, translational, and basic research findings focusing on the intersection of biomedical science and clinical practice.

With an ever-expanding portfolio of FDA-cleared devices for rapid AST directly from positive blood cultures, microbiology laboratories have more choices than ever.

One in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments, according to a new World Health Organization (WHO) report launched today.

US infections caused by New Delhi metallo-β-lactamase–producing carbapenem-resistant Enterobacterales (NDM-CRE) increased by more than 460% from 2019 to 2023, according to a Centers for Disease Control and Prevention (CDC) analysis published in the Annals of Internal Medicine.1-2 The agency warns that limited access to carbapenemase testing is hindering detection, delaying targeted therapy, and likely undercounting the true burden. To explore the diagnostics angle, and how faster, broader testing can strengthen stewardship, John Osiecki, PhD, vice president, medical affairs in North America at bioMérieux, spoke to Contagion on this significant need.

bioMérieux collaborates with Henry Ford Health to host a summit tackling the escalating threat of antimicrobial resistance, uniting healthcare leaders to promote effective diagnostics and stewardship.

This event will be chaired by Professor Angharad Davies, RCPath Clinical Director for Publishing and Engagement. A Q&A will follow the talks.

SPONSORED: Check out the new podcast by ID:IOTS with HIS Corporate Partners bioMérieux. Chloe Pinkney, Clinical Development Specialist, joins ID:IOTS podcast to talk about the launch of LUMED™ APSS™, a Clinical Decision Support System (CDSS) and how it is transforming Antimicrobial Stewardship by: 👉Identifying non-optimal antibiotic prescriptions 👉Supporting evidence-based treatment decisions 👉Reducing IV use and hospital stays 👉Enhancing patient safety and outcomes Listen now 🔗 https://lnkd.in/eJ8N_Khh

As personalized, life-saving treatments advance with the widespread adoption of cell and gene therapies (CGTs), diagnostic quality control partners face a critical challenge: adapting traditional methods to meet faster production timelines and the limited shelf life of cell therapy products while ensuring accuracy and reliability in results.

Dengue and chikungunya are endemic in West Africa, posing significant public health issues. The aim of this study was to evaluate the impact of differential and systematic diagnosis of dengue and chikungunya on patient management and on antibiotic use in Burkina Faso and Ivory Coast.

Patient associations across the globe are actively engaged in promoting this critical message to both healthcare professionals and the broader public. We met with Dr Rafael Moraes from ILAS, Melissa Mead from The UK Sepsis Trust and Thomas Heymann from Sepsis Alliance to learn more about their actions.

Studies show that the rapid administration of antibiotics has been generally associated with a decrease in deaths among hospitalized patients with sepsis. However, the need to quickly administer effective therapy can lead to clinicians turning to broad-spectrum antibiotics, which can exacerbate antimicrobial resistance (AMR). Because AMR is a major healthcare concern—including for patients with sepsis—improving the alignment between sepsis protocols and antimicrobial stewardship (AMS) guidelines is important for patient care.

Osteomyelitis – infection of the bone, and septic arthritis – joint infection, are serious medical conditions that can significantly impact a patient's quality of life. Bone and joint infections, often referred to as (BJIs), are notoriously difficult to treat and successful therapy requires organism-specific antimicrobial therapy at high doses for a prolonged duration.1 Diagnostics can support the identification and management of BJIs, while helping slow the progression of antimicrobial resistance (AMR).